Low-Dose Versus Standard-Dose Bevacizumab Plus Sintilimab for Unresectable Hepatocellular Carcinoma: A Real-World Comparative Study of Efficacy and Safety.

J Hepatocell Carcinoma · 2026 · PMC13086039 · PMID 42003878

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although these differences did not reach statistical significance, the numerically higher number of Sinti-Bev treatment cycles in the low-dose group may indicate improved tolerability and treatment adherence.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.